In last trading session, Kymera Therapeutics Inc (NASDAQ:KYMR) saw 1.42 million shares changing hands with its beta currently measuring 2.16. Company’s recent per share price level of $45.71 trading at -$0.76 or -1.64% at ring of the bell on the day assigns it a market valuation of $2.98B. That closing price of KYMR’s stock is at a discount of -16.54% from its 52-week high price of $53.27 and is indicating a premium of 57.47% from its 52-week low price of $19.44. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.67 million shares which gives us an average trading volume of 878.50K if we extend that period to 3-months.
For Kymera Therapeutics Inc (KYMR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Kymera Therapeutics Inc (NASDAQ:KYMR) trade information
Upright in the red during last session for losing -1.64%, in the last five days KYMR remained trading in the red while hitting it’s week-highest on Tuesday, 06/24/25 when the stock touched $45.71 price level, adding 4.23% to its value on the day. Kymera Therapeutics Inc’s shares saw a change of 45.34% in year-to-date performance and have moved -1.57% in past 5-day. Kymera Therapeutics Inc (NASDAQ:KYMR) showed a performance of 62.44% in past 30-days. Number of shares sold short was 7.58 million shares which calculate 7.15 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 59.5 to the stock, which implies a rise of 23.18% to its current value. Analysts have been projecting 54 as a low price target for the stock while placing it at a high target of 64. It follows that stock’s current price would drop -18.14% in reaching the projected high whereas dropping to the targeted low would mean a loss of -18.14% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -26.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -14.31% while estimates for its earnings growth in next 5 years are of -9.96%.
Kymera Therapeutics Inc (NASDAQ:KYMR)’s Major holders
Insiders are in possession of 2.69% of company’s total shares while institution are holding 111.66 percent of that, with stock having share float percentage of 114.75%. Investors also watch the number of corporate investors in a company very closely, which is 111.66% institutions for Kymera Therapeutics Inc that are currently holding shares of the company. PRICE T ROWE ASSOCIATES INC /MD/ is the top institutional holder at KYMR for having 6.39 million shares of worth $190.76 million. And as of 2024-06-30, it was holding 8.7472 of the company’s outstanding shares.
The second largest institutional holder is BAKER BROS. ADVISORS LP, which was holding about 6.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2069 of outstanding shares, having a total worth of $178.98 million.
